NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Thursday a 2 percent bump in revenues during its fiscal first quarter but missed analyst estimates on the top and bottom lines.

Total revenues for the three months ended Jan. 31 came in at $1.68 billion, up from $1.64 billion during the first quarter of Fiscal Year 2012, but just short of the average analyst estimate of $1.69 billion.

Orders in the quarter reached $1.71 billion, a 6 percent increase from $1.62 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.